Clinical Trials Logo
  1. Home
  2. Lymphoma, Non-Hodgkin
  3. NCT00903890
  4. Details
NCT00903890 Clinical Trial

Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin Clinical Trial

Official title:
Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma After Radiation Therapy/Anthracycline Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00903890
Other study ID # ULYM07056
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 2008
Est. completion date April 9, 2020

Study information
Verified date August 2023
Source University of Rochester
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is to inquire by mailed survey regarding the cardiac and general health of patients previously treated for Hodgkin's and non-Hodgkin's lymphoma with radiation therapy/anthracycline chemotherapy.

Recruitment information / eligibility
Status Completed
Enrollment 32
Est. completion date April 9, 2020
Est. primary completion date November 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patients with Hodgkin's Lymphoma and Non Hodgkin's lymphoma who underwent Radiation Therapy (RT) to either a mantle or modified mantle field with or without adriamycin at the Wilmot Cancer Center at the University of Rochester are eligible for the study. Exclusion Criteria: - Any severe preexisting cardiac disease (e.g., arrhythmia, angina, coronary disease, myocardial infarction, or congestive heart failure) prior to diagnosis

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Survey
Survey asking questions regarding the subjects cardiac and general health.

Locations
Country Name City State
United States University of Rochester Medical Center Rochester New York

Sponsors (1)
Lead Sponsor Collaborator
University of Rochester

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Measure changes in Cardiac ejection fraction score Post Radiation Treatment
Primary Measure changes in perfusion imaging score on the radionuclide cardiac profusion scan Post Radiation
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03484702 - Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma Phase 2
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Completed NCT06190457 - Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Completed NCT02369016 - Phase III Copanlisib in Rituximab-refractory iNHL Phase 3
Recruiting NCT01676805 - Tissue Collection for Studies of Lymph Cancer
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Withdrawn NCT00538096 - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma Phase 1
Completed NCT00534989 - Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT N/A
Terminated NCT00529503 - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL Phase 2
Completed NCT00156013 - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) Phase 1/Phase 2
Withdrawn NCT00319332 - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen Phase 3
Completed NCT00141297 - A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer Phase 1
Completed NCT00322842 - Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients Phase 2
Completed NCT02509039 - A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Phase 1
Completed NCT01573000 - A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) Phase 2
Completed NCT00268203 - Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma Phase 2
Completed NCT03289182 - An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)